Revvity, Inc. (NYSE:RVTY) posted third-quarter adjusted earnings on Monday that beat Wall Street estimates, prompting the company to upgrade its full-year earnings guidance while leaving its organic growth forecast unchanged.
The stock gained 0.72% in pre-market trading after the announcement.
For the quarter, the health science solutions firm reported adjusted earnings of $1.18 per share, exceeding analyst projections of $1.14. Revenue totaled $699 million, matching expectations of $699.39 million and marking a 2% year-over-year increase. Organic revenue rose 1% compared to the same period in 2024.
“We performed well during the third quarter as a number of key innovations and strategic partnerships have begun to come to fruition,” said Prahlad Singh, president and CEO of Revvity. “Our strong level of execution is positioning the Company for even greater success in 2026 and beyond.”
The Diagnostics division was the primary growth driver, with revenue climbing 3% to $356 million. Life Sciences also contributed, rising 1% to $343 million. However, both segments experienced a decline in adjusted operating margins versus last year.
The company revised its 2025 full-year revenue outlook to a range of $2.83 billion to $2.88 billion to reflect currency fluctuations, while reaffirming its organic growth guidance of 2% to 4%. It also raised its adjusted EPS forecast to $4.90–$5.00, above the consensus estimate of $4.87.
Revvity’s Board of Directors approved a fresh $1 billion share buyback program set to run for two years, replacing the remainder of the previous authorization announced in October 2024.